Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel
NASDAQ:ATRA

Atara Biotherapeutics Q1 2024 Earnings Report

Atara Biotherapeutics logo
$5.15 +0.39 (+8.19%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Atara Biotherapeutics EPS Results

Actual EPS
-$5.75
Consensus EPS
-$9.25
Beat/Miss
Beat by +$3.50
One Year Ago EPS
N/A

Atara Biotherapeutics Revenue Results

Actual Revenue
$27.36 million
Expected Revenue
$27.00 million
Beat/Miss
Beat by +$360.00 thousand
YoY Revenue Growth
N/A

Atara Biotherapeutics Announcement Details

Quarter
Q1 2024
Date
5/9/2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
4:15PM ET

Upcoming Earnings

Atara Biotherapeutics' Q1 2026 earnings is estimated for Wednesday, May 6, 2026, based on past reporting schedules

Conference Call Resources

Slide Deck

Atara Biotherapeutics' Q1 2024 Slide DeckFull Screen Slide Deck
Powered by Quartr

Earnings Documents

Atara Biotherapeutics' Q1 2024 Press ReleasePress Release
(8-K)
Atara Biotherapeutics' Q1 2024 Quarterly reportQuarterly report
(10-Q)

Atara Biotherapeutics Earnings Headlines

DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
May 6 at 12:08 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3289168/0/en/deadline-alert-for-lu-atra-and-coty-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-actions-on-behalf-of-shareholders.html
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
May 6 at 9:40 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atra-deadline-alert-faruqi--faruqi-llp-reminds-atara-biotherapeutics-atra-investors-of-securities-class-action-deadline-on-may-22-2026-302763785.html
Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.tc pixel
May 6 at 1:00 AM  |  InvestorPlace (Ad)
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
May 5 at 6:23 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288419/0/en/bragar-eagel-squire-p-c-reminds-atara-biotherapeutics-inc-investors-they-have-until-may-22nd-to-seek-lead-plaintiff-role-in-class-action-lawsuit.html
ROSEN, A LONGSTANDING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
May 5 at 5:38 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288396/673/en/rosen-a-longstanding-law-firm-encourages-atara-biotherapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-atra.html
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
May 5 at 4:46 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288338/1087/en/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-atara-biotherapeutics-inc-and-certain-officers-atra.html
See More Atara Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email.

About Atara Biotherapeutics

Atara Biotherapeutics (NASDAQ:ATRA) is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers. In addition, Atara is advancing multiple earlier-stage programs, including ATA188 for progressive multiple sclerosis and ATA227 for autoimmune indications, each harnessing the company’s expertise in antigen-specific T-cell biology. Atara’s pipeline is supported by manufacturing and process development capabilities aimed at delivering scalable, cryopreserved cell therapies for global distribution.

Founded in 2012, Atara Biotherapeutics has built a diversified clinical portfolio and established collaborations to advance its therapies across North America, Europe and Asia. The company’s leadership team combines expertise in cell therapy development, regulatory affairs and commercial strategy, guided by President and Chief Executive Officer Pascal Touchon. Through ongoing clinical studies and strategic partnerships, Atara aims to address unmet medical needs in oncology and autoimmune disease with its off-the-shelf T-cell products.

View Atara Biotherapeutics Profile
Earnings Tools